Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Bone Disorders

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Cushing Syndrome I: Introduction

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New and improved FRAX<sup>®</sup> for predicting fragility fractures: a work in progress.

Expert review of endocrinology & metabolism·2019

Same author

Postmenopausal osteoporosis: an update on current and future therapeutic options.

Expert review of endocrinology & metabolism·2019

Same author

Michael Kleerekoper (August 18, 1944 to May 10, 2018): In Relentless Pursuit of a Better Way.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2018

Same author

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2016

Same author

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2016

Same author

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

The Journal of bone and joint surgery. American volume·2014

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Glucocorticoid-induced osteoporosis.

Karen Koenig Berris¹, Anita Lopes Repp, Michael Kleerekoper

¹Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA.

Current Opinion in Endocrinology, Diabetes, and Obesity

|November 6, 2007

Summary

Glucocorticoid-induced osteoporosis is a major cause of secondary osteoporosis. Despite effective bisphosphonate treatments, this condition is often overlooked, leading to undertreatment and fractures.

Related Experiment Videos

Last Updated: Jul 10, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Area of Science:

Endocrinology
Bone Biology
Pharmacology

Background:

Glucocorticoid therapy is associated with significant bone loss, leading to secondary osteoporosis.
Glucocorticoid-induced osteoporosis (GIOP) is a leading cause of iatrogenic bone fragility.

Purpose of the Study:

To review the peer-reviewed literature on glucocorticoid-induced osteoporosis published since January 2006.
To provide an overview of current understanding and management strategies for GIOP.

Main Methods:

Literature review of studies published from January 2006 onwards.
Synthesis of findings related to pathophysiology, clinical presentation, and treatment of GIOP.

Main Results:

Pathophysiology of glucocorticoid-induced bone loss is better understood, particularly the role of the OPG/RANKL system.
Fracture risk in GIOP may be underestimated by bone mineral density, as fractures occur at higher BMD than in other osteoporosis types.
Bisphosphonates are the primary treatment, yet GIOP remains underrecognized and undertreated.

Conclusions:

GIOP is a significant consequence of glucocorticoid use, contributing to secondary osteoporosis.
Bone mineral density may not fully capture fracture risk in GIOP, contributing to underdiagnosis.
Improved recognition and treatment are crucial to mitigate the impact of GIOP.